Riskpilot← Back to searchSign inGet full accessCaroderma AB
ABActiveOrg 5592138696Karlaplan 19 C 2tr Lgh 1201Medical specialists activities · NACE 8622Est. 20191 employees
Revenue 2024
SEK 192K
+25% vs 2023
EBITDA margin
49.5%
-13% vs 2023
Equity ratio
58.2%
Financial strength
Net profit 2024
SEK 67K
-22% vs 2023
| Revenue | SEK 192K | +25% |
| EBITDA | SEK 95K | -13% |
| Net profit | SEK 67K | -22% |
| Total assets | SEK 208K | -25% |
| Equity | SEK 121K | -41% |
| Employees | 1 | — |
Legal name
Caroderma AB
Org number
5592138696
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
1 augusti 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva medicinsk hälso- och sjukvård, medicinsk och kirurgisk hudsjukvård, kosmetisk hudvård och utbildning inom hälsa- och sjukvård samt konsultation, rådgivning och kommunikation inom medicin och dermatologi. Därtill äga och förvalta fast och lös egendom, inredning samt idka därmed förenlig verksamhet.
Address
Karlaplan 19 C 2tr Lgh 1201
Email
caroline.danell@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 90 | 81 | 51 | 154 | 192 |
| Staff expenses | — | — | −8 | — | — |
| EBITDA | 26 | 44 | 24 | 109 | 95 |
| Depreciation & amort. | −0 | −0 | — | −0 | −0 |
| EBIT | 26 | 44 | 24 | 109 | 95 |
| Net financials | — | — | −6 | — | 1 |
| Profit before tax | 27 | 44 | 18 | 109 | 95 |
| Tax | −6 | −9 | −6 | −23 | −28 |
| Net profit | 21 | 35 | 12 | 86 | 67 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 130 | 163 | 128 | 278 | 208 |
| Equity | 71 | 105 | 118 | 204 | 121 |
| Long-term debt | 0 | 0 | — | 0 | 0 |
| Short-term debt | 59 | 58 | 10 | 74 | 88 |
| Total debt | 59 | 58 | 10 | 74 | 88 |
EBITDA margin
49.5%
This company
15.8%
Market median
+213% vs market
20202024
Equity ratio
58.2%
This company
38.2%
Market median
+52% vs market
20202024
Return on equity
55.4%
This company
18.4%
Market median
+201% vs market
20202024
Net profit margin
34.9%
This company
8.1%
Market median
+331% vs market
20202024
Asset turnover
0.92×
This company
1.12×
Market median
+18% vs market
20202024
Debt / equity
0.72×
This company
0.62×
Market median
+16% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-08-01 – 2020-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Caroderma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Caroline Liora Danell | Board of Directors | 0 companies |
| Claes Eric Josef Danell | Deputy Board Member | 0 companies |